Synergistic Cytotoxicity of Lenalidomide and Dexamethasone in Mantle Cell Lymphoma via Cereblon-dependent Targeting of the IL-6/STAT3/PI3K Axis

At our center, relapsed mantle cell lymphoma (MCL) can be treated with maintenance therapy composed of consecutive low-dose lenalidomide and short-term, high-dose dexamethasone (LD regimen), which achieves good responses (longer overall survival and progression-free survival) and low toxicity. Cereb...

Descripción completa

Detalles Bibliográficos
Autores principales: Ma, Jiexian, Wu, Kefei, Bai, Weiya, Cui, Xiaoxian, Chen, Yan, Xie, Youhua, Xie, Yanhui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5478233/
https://www.ncbi.nlm.nih.gov/pubmed/28529032
http://dx.doi.org/10.1016/j.ebiom.2017.04.037

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5478233/
https://www.ncbi.nlm.nih.gov/pubmed/28529032
http://dx.doi.org/10.1016/j.ebiom.2017.04.037

Ejemplares similares